ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Aventis Pharma Limited

Aventis Pharma Limited is an active company incorporated on 18 December 1980 with the registered office located in Reading, Berkshire. Aventis Pharma Limited was registered 45 years ago.
Status
Active
Active since 25 years ago
Company No
01535640
Private limited company
Age
45 years
Incorporated 18 December 1980
Size
Large
Turnover is over £54M
Balance sheet is over £27M
Over 250 employees
Confirmation
Submitted
Dated 22 December 2025 (1 month ago)
Next confirmation dated 22 December 2026
Due by 5 January 2027 (11 months remaining)
Last change occurred 4 years ago
Accounts
Submitted
For period 1 Jan31 Dec 2024 (1 year)
Accounts type is Full
Next accounts for period 31 December 2025
Due by 30 September 2026 (8 months remaining)
Contact
Address
410 Thames Valley Park Drive
Reading
Berkshire
RG6 1PT
England
Same address for the past 6 years
Telephone
01142843200
Email
Available in Endole App
People
Officers
2
Shareholders
1
Controllers (PSC)
1
Director • British • Lives in UK • Born in Dec 1978
Director • British • Lives in UK • Born in Jun 1979
Sanofi-Aventis UK Holdings Limited
PSC
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Fisons Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
Sanofi-Synthelabo UK Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
Rhone-Poulenc Rorer Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
May & Baker Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
Sanofi-Aventis UK Holdings Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
RPR (Us) Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
Aventis Pharma Holdings Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
Genzyme Therapeutics Limited
Usman Khan and Rippondeep Ubhi are mutual people.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2015–2024)
Period Ended
31 Dec 2024
For period 31 Dec31 Dec 2024
Traded for 12 months
Cash in Bank
£131K
Decreased by £13K (-9%)
Turnover
£414.63M
Increased by £16.85M (+4%)
Employees
585
Decreased by 81 (-12%)
Total Assets
£1.86B
Decreased by £413.95M (-18%)
Total Liabilities
-£443.37M
Decreased by £302.09M (-41%)
Net Assets
£1.42B
Decreased by £111.86M (-7%)
Debt Ratio (%)
24%
Decreased by 8.95% (-27%)
Latest Activity
Confirmation Submitted
17 Days Ago on 5 Jan 2026
Full Accounts Submitted
1 Month Ago on 5 Dec 2025
Rippon Ubhi Details Changed
8 Months Ago on 14 May 2025
Confirmation Submitted
11 Months Ago on 9 Feb 2025
Full Accounts Submitted
1 Year 6 Months Ago on 15 Jul 2024
Rippon Ubhi Appointed
1 Year 10 Months Ago on 1 Mar 2024
Jessamy Rachel Baird Resigned
1 Year 10 Months Ago on 1 Mar 2024
Confirmation Submitted
1 Year 12 Months Ago on 25 Jan 2024
Full Accounts Submitted
2 Years 3 Months Ago on 25 Oct 2023
Confirmation Submitted
3 Years Ago on 6 Jan 2023
Get Credit Report
Discover Aventis Pharma Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Confirmation statement made on 22 December 2025 with no updates
Submitted on 5 Jan 2026
Full accounts made up to 31 December 2024
Submitted on 5 Dec 2025
Second filing for the appointment of Rippondeep Ubhi as a director
Submitted on 27 May 2025
Director's details changed for Rippon Ubhi on 14 May 2025
Submitted on 19 May 2025
Confirmation statement made on 22 December 2024 with no updates
Submitted on 9 Feb 2025
Full accounts made up to 31 December 2023
Submitted on 15 Jul 2024
Appointment of Rippon Ubhi as a director on 1 March 2024
Submitted on 3 Mar 2024
Termination of appointment of Jessamy Rachel Baird as a director on 1 March 2024
Submitted on 1 Mar 2024
Confirmation statement made on 22 December 2023 with no updates
Submitted on 25 Jan 2024
Full accounts made up to 31 December 2022
Submitted on 25 Oct 2023
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year